All news

Boston Scientific (BSX) Lands $455 Million Blackstone Backing, Is The 26% Undervaluation Case Intact?

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Boston Scientific (BSX) has secured up to US$455 million from Blackstone Life Sciences to co-fund the development of its VITALYST heart pump. Despite a recent share price dip, the stock is considered 26% undervalued with a fair value of $57.82 against a current close of $42.75, based on its product pipeline and cost-saving initiatives.

Read original source

BSX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.